Advanced differentiated thyroid cancer: when to stop radioiodine?.
Advanced differentiated thyroid cancer: when to stop radioiodine?.
- 2019
Radioiodine (RAI) is a pivotal important treatment for patients with metastatic differentiated thyroid cancer (DTC). In order to determine when a patient will no longer respond to RAI, multiple classifications have been described to categorize a patient as radioiodine refractory (RAI-R). Current classifications, although very useful, are problematic and controversial and cannot be merely applied in the context of individualized patient management. In addition, classifications on how to define RAI-R disease are continuosly evolving as more studies are published and managing physicians better understand the limitations and confounding factors of present classifications. Accordingly, each patient should be individually managed with a good understanding of the limitations of the various classifications, assessing the many other factors that affect the patient's specific clinical situation and delivering appropriate individualized patient care.
English
1824-4785
10.23736/S1824-4785.19.03191-1 [doi] S1824-4785.19.03191-1 [pii]
*Iodine Radioisotopes/tu [Therapeutic Use]
*Thyroid Neoplasms/pa [Pathology]
*Thyroid Neoplasms/rt [Radiotherapy]
Disease Progression
Humans
Treatment Outcome
MedStar Washington Hospital Center
Medicine/Nuclear Medicine
Journal Article
Radioiodine (RAI) is a pivotal important treatment for patients with metastatic differentiated thyroid cancer (DTC). In order to determine when a patient will no longer respond to RAI, multiple classifications have been described to categorize a patient as radioiodine refractory (RAI-R). Current classifications, although very useful, are problematic and controversial and cannot be merely applied in the context of individualized patient management. In addition, classifications on how to define RAI-R disease are continuosly evolving as more studies are published and managing physicians better understand the limitations and confounding factors of present classifications. Accordingly, each patient should be individually managed with a good understanding of the limitations of the various classifications, assessing the many other factors that affect the patient's specific clinical situation and delivering appropriate individualized patient care.
English
1824-4785
10.23736/S1824-4785.19.03191-1 [doi] S1824-4785.19.03191-1 [pii]
*Iodine Radioisotopes/tu [Therapeutic Use]
*Thyroid Neoplasms/pa [Pathology]
*Thyroid Neoplasms/rt [Radiotherapy]
Disease Progression
Humans
Treatment Outcome
MedStar Washington Hospital Center
Medicine/Nuclear Medicine
Journal Article